About
Approach
Investment Model
Investment Scope
Our approach
Team
Managing Partner
Partners
Our team
Portfolio
News
Connect
Chime Biologics and Daewoong Pharmaceutical Enter Strategic Partnership to Advance Dupilumab Biosimilar Development and Commercialization in Global Markets
Article Date
June 1, 2026
This article is featured on another website.
Go to article
Related posts
Browse all articles
August 13, 2026
The Oligodendrocyte Advantage
August 13, 2026
The Oligodendrocyte Advantage
July 14, 2026
Chime Biologics Congratulates Polpharma Biologics on Global Licensing Agreement with Teva for Ocrelizumab Biosimilar Candidate
July 14, 2026
Chime Biologics Congratulates Polpharma Biologics on Global Licensing Agreement with Teva for Ocrelizumab Biosimilar Candidate
